Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DRTS
DRTS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DRTS News
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
Jan 23 2026
NASDAQ.COM
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
Jan 14 2026
Benzinga
Alpha Tau Medical Submits FDA Application for Alpha DaRT Therapy
Jan 06 2026
NASDAQ.COM
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
Jan 06 2026
NASDAQ.COM
Alpha Tau Medical to Present Alpha DaRT® Progress at J.P. Morgan Healthcare Conference
Dec 18 2025
Newsfilter
Alpha Tau Administers Alpha DaRT to First U.S. Brain Cancer Patient; Stock Prices Rise Following Milestone
Dec 10 2025
NASDAQ.COM
What Caused Alpha Tau Medical (DRTS) Shares to Surge More Than 25% in After-Hours Trading?
Dec 10 2025
Benzinga
Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers
Dec 10 2025
NASDAQ.COM
Alpha Tau Treats First Brain Cancer Patient with Alpha DaRT Technology
Dec 09 2025
Globenewswire
Alpha Tau Medical Receives FDA Approval for Prostate Cancer Clinical Trial
Dec 02 2025
Newsfilter
Alpha Tau Medical to Present at Two Investor Conferences in December 2025
Dec 01 2025
Globenewswire
Alpha Tau Medical CFO to Present at Two Investor Conferences in December 2025
Dec 01 2025
Newsfilter
Alpha Tau Aims for Year-End Approval in Japan for Alpha DaRT Therapy in Recurrent Head and Neck Cancer
Nov 21 2025
NASDAQ.COM
HC Wainwright & Co. Affirms Buy Rating for Alpha Tau Medical, Keeps $9 Price Target Intact
Oct 22 2025
Benzinga
Alpha Tau Achieves First Patient Treatment in U.S. Multi-Center Clinical Trial for Pancreatic Cancer
Sep 02 2025
Newsfilter
Alpha Tau to Attend Five Investor Conferences in September
Aug 27 2025
Newsfilter
Show More News
